Among these, liraglutide in the LEADER study, semaglutide in the SUSTAIN-6, albiglutide in the Harmony Outcomes, dulaglutide in the REWIND, and efpeglenatide in the AMPLITUDE-O exhibited significant beneficial effects on 3-point major adverse cardiac events (3P-MACE: death from CV disease, non-fatal myocardial infarction, and non-fatal stroke), the primary end point of each study, compared to the placebo group, respectively
Not willing to give up, Holst turned to Thue Schwartz, a young Danish medical student and molecular pharmacologist working with Rehfeld on gastrin and new peptides isolated from the pancreas
Further, T2DM remains one of the most significant risk factors not only for the development of MASLD but also for the progression of liver fibrosis and the occurrence of liverrelated complications, including HCC (Leith et al., 2024
| Simeon Panda